For these purposes, VEGFR2 was selected as a target gene based on prior research involving the designed peptide VGB4, known for its ability to bind to VEGFR2 and inhibit VEGF-A, thereby reducing cancer cell proliferation in the U87-MG glioblastoma cell line [26]. The gene discussed is KDR; the disease is glioblastoma.